Picture of PCI Biotech Holding ASA logo

PCIBo PCI Biotech Holding ASA Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-3.3%
3m-18.13%
6m-48.45%
1yr-59.65%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-56.92%
Return on Equity-42.13%
Operating Margin-743.85%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of PCI Biotech Holding ASA EPS forecast chart

Profile Summary

PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
March 19th, 2007
Public Since
June 18th, 2008
No. of Employees
7
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
37,326,390

PCIBo Share Price Performance

Upcoming Events for PCIBo

Q1 2024 PCI Biotech Holding ASA Earnings Release

PCI Biotech Holding ASA Annual Shareholders Meeting

Q2 2024 PCI Biotech Holding ASA Earnings Release

Similar to PCIBo

Picture of 2cureX AB logo

2cureX AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Abliva AB logo

Abliva AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Active Biotech AB publ logo

Active Biotech AB publ

se flag iconOMX Nordic Exchange Stockholm

Picture of AddLife AB logo

AddLife AB

se flag iconOMX Nordic Exchange Stockholm

FAQ